Aprotinin and major orthopedic surgery

  • Charles Marc Samama


Aprotinin is a potent pharmacological agent that reduces bleeding and limits blood transfusion requirements in current surgical practice. Many studies have been conducted in orthopedic surgery. In several trials performed in total hip replacement (THR) and total knee replacement (TKN) patients, aprotinin only moderately decreased blood-loss-replacement requirements. Conversely, when aprotinin was used in patients at high risk for bleeding (cancer, sepsis, redone surgery), it developed a potent hemostatic activity and decreased blood transfusion significantly. No increase in deep vein thrombosis and pulmonary embolism was observed. The only major side effect could be the potential occurrence of an anaphylactoid reaction. Prophylactic administration of aprotinin should be considered in extensive spine surgery and in high-risk major orthopedic operations. The decision to use aprotinin should be guided by a risk/ benefit analysis.


Aprotinin Bleeding Transfusion Orthopaedic surgery Thrombosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A (1998) Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 116:716–730PubMedGoogle Scholar
  2. 2.
    Amar D, Grant FM, Zhang H, Boland PJ, Leung DH, Healey JA (2003) Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. Anesthesiology 98: 337–342CrossRefPubMedGoogle Scholar
  3. 3.
    Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, D’Athis F (1998) Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology 88:50–57CrossRefPubMedGoogle Scholar
  4. 4.
    Cosgrove D 3rd, Heric B, Lytle B, Taylor P, Novoa R, Golding L, Stewart L, McCarthy P, Loop FD (1992) Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 54: 1031–1038PubMedGoogle Scholar
  5. 5.
    Dewachter P, Mouton C, Masson C, Gueant JL, Haberer JP (1993) Anaphylactic reaction to aprotinin during cardiac surgery [letter]. Anaesthesia 48: 1110–1111PubMedGoogle Scholar
  6. 6.
    Diefenbach C, Abel M, Limpers B, Lynch J, Ruskowski H, Jugert FK, Buzello W (1995) Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg 80:830–831CrossRefPubMedGoogle Scholar
  7. 7.
    Dietrich W (1998) Incidence of hypersensitivity reactions. Ann Thorac Surg 65[Suppl]:S60–S74CrossRefPubMedGoogle Scholar
  8. 8.
    Engel JM, Hohaus T, Ruwoldt R, Menges T, Jurgensen I, Hempelmann G (2001) Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. Anesth Analg 92:775–780CrossRefPubMedGoogle Scholar
  9. 9.
    Espana F, Estelles A, Griffin J, Aznar J, Gilabert J (1989) Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Thromb Res 56:751–756CrossRefPubMedGoogle Scholar
  10. 10.
    Fitzsimons MG, Peterfreund RA, Raines DE (2001) Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 92:1418–1421CrossRefPubMedGoogle Scholar
  11. 11.
    Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB (2001) Prevention of venous thromboembolism. Chest 119:132S–175SCrossRefPubMedGoogle Scholar
  12. 12.
    Godet G, Bertrand M, Samama CM, Barré E, Fléron MH, Baron JF, Coriat P, Kieffer E, Viars P (1994) Aprotinin decreases blood loss and blood transfusion requirements in thoracic and thoraco-abdominal aortic surgery under extra-corporeal circulation. Ann Vasc Surg 8:452–456PubMedGoogle Scholar
  13. 13.
    Hayes A, Murphy DB, McCarroll M (1996) The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 8:357–360CrossRefPubMedGoogle Scholar
  14. 14.
    Janssens M, Joris J, David JL, Lemaire R, Lamy M (1994) High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 80:23–29PubMedGoogle Scholar
  15. 15.
    Jeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R (2003) Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery. A prospective, double blind, randomized and placebo-controlled study. J Bone Joint Surg Br 85B: 174–177CrossRefGoogle Scholar
  16. 16.
    Kasper SM, Elsner F, Hilgers D, Grond S, Rutt J (1998) A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol 15:669–675PubMedGoogle Scholar
  17. 17.
    Khoshhal K, Mukhtar I, Clark P, Jarvis J, Letts M, Splinter W (2003) Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. J Pediatr Orthop 23:661–664PubMedGoogle Scholar
  18. 18.
    Kovesi T, Royston D (2003) Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang 84: 2–10CrossRefPubMedGoogle Scholar
  19. 19.
    Langdown AJ, Field J, Grote J, Himayat H (2000) Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty 15: 1009–1012CrossRefPubMedGoogle Scholar
  20. 20.
    Lentschener C, Cottin P, Bouaziz H, Mercier FJ, Wolf M, Aljabi Y, Boyer-Neumann C, Benhamou D (1999) Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 89: 590–597CrossRefPubMedGoogle Scholar
  21. 21.
    Levy JH, Bailey JM, Salmenpera M (1994) Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 80:1013–1018PubMedGoogle Scholar
  22. 22.
    Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G (1995) Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 80:343–348CrossRefPubMedGoogle Scholar
  23. 23.
    Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB (2000) Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am 82: 675–684PubMedGoogle Scholar
  24. 24.
    Porte RJ, Leebeek FWG (2002) Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 62:2193–2211PubMedGoogle Scholar
  25. 25.
    Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT, for the EMSALT Study Group (2000) Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 355: 1303–1309CrossRefPubMedGoogle Scholar
  26. 26.
    Royston D, Bistrup BP, Taylor KM, Sapsford RN (1987) Effects of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2:1289–1291CrossRefPubMedGoogle Scholar
  27. 27.
    Samama CM, Dietrich W, Horrow J, Taby O, Samama MM (2000) Structure, pharmacology, and clinical use of antifibrinolytic agents. In: Bachman F (ed) Handbook of experimental pharmacology. fibrinolytics and antifibrinolytics. Springer, Berlin Heidelberg New York, pp 559–585Google Scholar
  28. 28.
    Samama CM, Langeron O, Rosencher N, Capdevila N, Rouche P, Pegoix M, Bernière J, Coriat P, for the HACOL Study Group (2002) Aprotinin versus placebo in major orthopedic surgery: a randomized double-blinded doseranging study. Anesth Analg 95:287–293CrossRefPubMedGoogle Scholar
  29. 29.
    Thorpe CM, Murphy WG, Logan M (1994) Use of aprotinin in knee-replacement surgery. Br J Anaesth 73: 408–410PubMedGoogle Scholar
  30. 30.
    Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O (2001) The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive surgery. Spine 26: 1152–1157CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Charles Marc Samama
    • 1
  1. 1.Département d’Anesthésie-RéanimationHôpital AvicenneBobigny cedexFrance

Personalised recommendations